Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01822509
Title Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)

multiple myeloma

hematologic cancer

Hodgkin's lymphoma

chronic myeloid leukemia

acute leukemia

myelodysplastic syndrome

non-Hodgkin lymphoma

myelodysplastic/myeloproliferative neoplasm

chronic lymphocytic leukemia


Ipilimumab + Nivolumab

Age Groups: adult
Covered Countries USA

No variant requirements are available.